Clinical trials: Breast
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8
Durvalumab and Tremelimumab Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Stage II-III Breast Cancer
This early phase I trial studies the side effects of durvalumab and tremelimumab before surgery in treating patients with hormone receptor positive, HER2 negative stage II-III breast cancer.
- Conditions
- Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
- Trial name
- NCT03132467
- Testing
- Durvalumab, Tremelimumab
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer, Hepatitis C
Association of Hepatitis C Virus With Breast Cancer
Hepatitis C viral infection is a major health problem in Egypt. The management of breast cancer patients is often complicated by the presence of associated HCV infection.
- Trial name
- NCT04090164
- Where
- Egypt
- Volunteers
- 650 people, healthy volunteers welcome
- Sponsor
- Mansoura University
Breast Cancer
Exemestane in Combination With Fulvestrant in Postmenopausal Women With Hormone Sensitive Advanced Breast Cancer
The purpose of this trial is to evaluate time to progression in women with hormone responsive advanced breast cancer treated with a combination of exemestane and fulvestrant.
- Trial name
- NCT00201864
- Testing
- Exemestane, Fulvestrant
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Breast Cancer
Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer
This randomized phase III trial studies cyclophosphamide and doxorubicin hydrochloride compared with paclitaxel as adjuvant therapy in treating breast cancer in women with 0-3 positive axillary lymph nodes.
- Trial name
- NCT00041119
- Testing
- AC regimen, cyclophosphamide, doxorubicin hydrochloride
- Where
- 527 sites in United States, South Africa
- Volunteers
- 3,871 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Metastatic Breast Cancer
Standard Versus Continuous Capecitabine in Advanced Breast Cancer
Capecitabine is active in metastatic breast cancer but the conventional schedule (1250 mg/m2/12 hr 2 weeks on, one week off) produces grade 2 or greater hand and foot syndrome in up to 50% of patients leading to those reductions.
- Trial name
- NCT00418028
- Testing
- Capecitabine
- Where
- Spain
- Volunteers
- 195 people
- Sponsor
- Hospital San Carlos, Madrid
Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast
A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations
This is an open-label, multi-center, single arm, Phase II study to evaluate the efficacy and safety of T-DXd for the treatment of unresectable and/or metastatic solid tumors harboring specific HER2 activating mutations regardless…
- Trial name
- DPT01 (NCT04639219)
- Testing
- Trastuzumab deruxtecan
- Where
- 30 sites in United States, Belgium and 7 more
- Volunteers
- 102 people
- Sponsor
- AstraZeneca
Breast Cancer, Mastectomy
Acellular Dermal Matrix in Tissue Expander Breast Reconstruction: A Prospective, Randomized, Clinical Trial Comparing SurgiMend PRS and AlloDerm RTU
The purpose of this study is to assess the relative performance and complication rates between the AlloDerm RTU and SurgiMend PRS products as well as the relative economics of these two treatment options.
- Trial name
- NCT01781299
- Testing
- AlloDerm RTU, SurgiMend PRS
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Pittsburgh
Cancer, Pain
Improving Cancer Pain Management Through Self-Care
This study will test two different doses of a psychoeducational intervention to improve cancer pain management. In addition, the study will determine if the changes in pain management behaviors that the patients and family…
- Trial name
- NCT00708019
- Testing
- PRO-SELF PLUS Pain Management Program
- Where
- 2 sites in United States
- Volunteers
- 185 people
- Sponsor
- University of California, San Francisco
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)
This phase II MATCH treatment trial identifies the effects of GDC-0032 (taselisib) in patients whose cancer has a genetic change called PIK3CA mutation.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma
- Trial name
- NCT04439175
- Testing
- Taselisib
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Breast Cancer
Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic
The purpose of this study is to find out what effect the combination of letrozole (brand name: Femara) and dasatinib (brand name: Sprycel) has on metastatic breast cancer compared to letrozole alone
- Trial name
- NCT00696072
- Testing
- Dasatinib, Letrozole
- Where
- 27 sites in United States
- Volunteers
- 120 people
- Sponsor
- Bristol-Myers Squibb
Breast Cancer - Female
Melatonin Supplementation for Cancer-related Fatigue in Patients Receiving Radiotherapy
This is a double-blind, placebo-controlled trial wherein subjects with breast cancer will be randomized to receive either 20 mg oral melatonin or placebo the night before their first radiotherapy (RT), nightly throughout their…
- Trial name
- NCT02332928
- Testing
- Melatonin
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Virginia Commonwealth University
Breast Cancer, Cancer Survivor
Magnesium Oxide in Treating Postmenopausal Women With Hot Flashes and a History of Breast Cancer
RATIONALE: Magnesium oxide may help relieve hot flashes symptoms in women with a history of breast cancer. PURPOSE: This randomized clinical trial studies how well a high-dose or a low-dose of magnesium oxide works compared to…
- Conditions
- Breast Cancer, Cancer Survivor, Hot Flashes
- Trial name
- NCT01439945
- Testing
- magnesium oxide
- Where
- 283 sites in United States
- Volunteers
- 289 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Breast Cancer
Dose Dense Adjuvant CMF (Cyclophosphamide, Methotrexate, Fluorouracil) at 14 and 10-11 Day Intervals for Women With Early Stage Breast Cancer
CMF (cyclophosphamide, methotrexate, fluorouracil) is used to treat early stage breast cancer. The combination, of these three drugs, has been used for approximately 30 years in the treatment of breast cancer, and has been shown…
- Trial name
- NCT00615901
- Testing
- cyclophosphamide, methotrexate, fluorouracil, PEG-filgrastim
- Where
- 5 sites in United States
- Volunteers
- 38 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Carcinoma, Recurrent Breast Carcinoma
Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU
This randomized phase III trial studies first-line chemotherapy and trastuzumab to compare how well they work when given with or without bevacizumab in treating patients with breast cancer that overexpresses human epidermal…
- Conditions
- Breast Carcinoma, Recurrent Breast Carcinoma, Stage IV Breast Cancer
- Trial name
- NCT00520975
- Testing
- Bevacizumab, Carboplatin, Paclitaxel
- Where
- 373 sites in United States
- Volunteers
- 96 people
- Sponsor
- National Cancer Institute (NCI)
Breast Neoplasms
Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer
To compare the sequential administration of exemestane with administration of further tamoxifen until 5 years in postmenopausal women with operable breast cancer who have already received 2-3 years of adjuvant tamoxifen, in terms…
- Trial name
- IES (NCT00038467)
- Testing
- Tamoxifen, Exemestane
- Where
- 377 sites in United States, Argentina and 35 more
- Volunteers
- 4,740 people
- Sponsor
- Pfizer
Breast Cancer
A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer
This study is being done for the following reasons: The study has two parts. The purpose of the first part (Phase I) of the study is to find out the highest dose of neratinib that can be given safely with T-DM1.
- Trial name
- NCT02236000
- Testing
- Neratinib, T-DM1
- Where
- 15 sites in United States
- Volunteers
- 49 people
- Sponsor
- NSABP Foundation Inc
Breast Cancer
Focused Ultrasound and Pembrolizumab in Metastatic Breast Cancer
This pilot study evaluates the use of high-intensity focused ultrasound (HIFU) combined with pembrolizumab in patients with metastatic breast cancer.
- Trial name
- Breast-48 (NCT03237572)
- Testing
- Pembrolizumab, High-intensity focused ultrasound (HIFU)
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Patrick Dillon, MD
Metastatic Breast Cancer
Combination Chemotherapy of Gemcitabine and Paclitaxel for Metastatic Breast Cancer
To investigate efficacy, safety and PK of gemcitabine and paclitaxel combination in patients with metastatic breast cancer after adjuvant/neo-adjuvant chemotherapy with anthracycline regimen
- Trial name
- NCT00334802
- Testing
- gemcitabine, paclitaxel
- Where
- 15 sites in Japan
- Volunteers
- 62 people
- Sponsor
- Eli Lilly and Company
Breast Carcinoma, Cervical Carcinoma
Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer
This phase II randomized trial studies how well bupropion hydrochloride works in improving sexual desire in women with breast or gynecological cancer.
- Conditions
- Breast Carcinoma, Cervical Carcinoma, Ovarian Carcinoma, Postmenopausal
- Trial name
- NCT03180294
- Testing
- Bupropion 150 mg XL
- Where
- 362 sites in United States
- Volunteers
- 230 people
- Sponsor
- NRG Oncology
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma
Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)
This phase II ComboMATCH treatment trial compares the usual treatment alone (fulvestrant) to using binimetinib plus the usual treatment in patients with hormone receptor positive breast cancer that has spread from where it first…
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma
- Trial name
- NCT05554354
- Testing
- Binimetinib, Biopsy Procedure, Biospecimen Collection
- Where
- 196 sites in United States, Puerto Rico
- Volunteers
- 1 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.